U.S. must address IP and market access barriers abroad to protect American innovation

PhRMA recently submitted comments to the Office of the U.S. Trade Representative (USTR)’s 2023 Special 301 Report. The comments highlight foreign government actions and policies that undermine...
Read More
Word of the Month: What is TRIPS?

What is TRIPS?
Read More
TRIPS waiver expansion risks public health

The Biden administration and other World Trade Organization members are considering expanding the harmful and unnecessary waiver of intellectual property (IP) protections under the Agreement on...
Read More
Expanding the WTO intellectual property waiver will hurt American jobs

The June decision by WTO members to waive commitments to protect intellectual property (IP) for COVID-19 vaccines under the Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement was...
Read More
Word of the Month: Long COVID

What is Long COVID?
Read More
Protecting against influenza: A conversation with David Ross, Vice President, Commercial Operations, North America, CSL Seqirus

Our industry is at the forefront of fighting the annual influenza virus. I recently had the chance to connect with David Ross, Vice President, Commercial Operations, North America, CSL Seqirus about...
Read More
Partnerships are driving global COVID-19 treatment access

Through the constant efforts of U.S. innovators and their global partners, COVID-19 treatments have continued to be distributed to patients around the world — changing the pandemic’s treatment...
Read More
The dangers of expanding the TRIPS waiver

World Trade Organization (WTO) members, including the United States, are considering waiving commitments to honor certain intellectual property (IP) rights on COVID-19 treatments, following a harmful...
Read More
ICYMI: New research builds upon growing body of evidence on value of COVID-19 treatments and vaccines

Innovative biopharmaceutical research companies have been dedicated to fighting COVID-19 for over two years. Since the start of the pandemic, America’s biopharmaceutical companies have worked around...
Read More
ICYMI: PhRMA’s Ubl pens op-ed on IP waiver for COVID-19 technologies

Member states of the World Trade Organization (WTO) recently agreed to a waiver of intellectual property (IP) protections for COVID-19 vaccines as part of the Trade-Related Aspects of Intellectual...
Read More